Richard B. Stead
Non-Executive Director
Oncology
Ascend Biopharmaceuticals
Australia
Biography
Dr. Richard Stead has more than 25 years of experience in the biotechnology and pharmaceutical industries, designing and directing clinical trials, regulatory strategy and licensing activities. He is currently Founder and Principal of BioPharma Consulting Services, where he is involved in the development of a number of oncology products including different strategies for cancer immunotherapy. He also serves as an independent director on the board of Affimed Therapeutics AG, a privately held German company developing next generation bispecific antibodies in oncology. Previously, he was Vice President, Clinical Research of Immunex Corporation with responsibilities including oncology and neurology product development. Dr. Stead has served in various positions in clinical development and played a key role in the FDA approval and commercialisation of Amgen’s first two products, Epogen and Neupogen. MD, Stanford University.
Research Interest
Oncology
